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With an increased prevalence and understanding of central nervous system (CNS)
injuries and neurological disorders, nucleic acid therapies are gaining promise as a
way to regenerate lost neurons or halt disease progression. While more viral vectors
have been used clinically as tools for gene delivery, non-viral vectors are gaining
interest due to lower safety concerns and the ability to deliver all types of nucleic
acids. Nevertheless, there are still a number of barriers to nucleic acid delivery. In
this focused review, we explore the in vivo challenges hindering non-viral nucleic acid
delivery to the CNS and the strategies and vehicles used to overcome them. Advantages
and disadvantages of different routes of administration including: systemic injection,
cerebrospinal fluid injection, intraparenchymal injection and peripheral administration
are discussed. Non-viral vehicles and treatment strategies that have overcome delivery
barriers and demonstrated in vivo gene transfer to the CNS are presented. These
approaches can be used as guidelines in developing synthetic gene delivery vectors for
CNS applications and will ultimately bring non-viral vectors closer to clinical application.
Keywords: central nervous system, delivery, in vivo, non-viral, nucleic acid
INTRODUCTION
The incidence of neurological diseases and injuries is increasing with the rising life expectancy
(Mattson and Magnus, 2006). Nucleic acid therapeutics, such as genes and small interfering
RNA (siRNA) oligonucleotides have emerged as a promising treatment strategy to preserve
neuron function, enhance neurogenesis and prevent the progression of neurological diseases.
The delivery of nucleic acids encoding brain-derived neurotrophic factor (Huang et al., 2012a),
epidermal growth factor (Sugiura et al., 2005), fibroblast growth factor-2 (Matsuoka et al.,
2003), Huntingtin (Burgess et al., 2012), neurogenin-2 (Zhang et al., 2013; Masserdotti et al.,
2015), insulin growth factor-1 (Kaspar et al., 2003), and vascular endothelial growth factor
(Dodge et al., 2010) have been shown to increase neuron regeneration or delay the progression
of neurological diseases in mice, rats and gerbils. Targeting gene delivery vehicles to the
appropriate cells and proper protein regulation remain the primary challenges to making
these pathways feasible. While viral vectors such as the adeno-associated virus have typically
been used clinically, interest in non-viral nucleic acid delivery remains high due to lower
safety concerns, greater customizability and an ease in manufacturing (Pack et al., 2005; Burke
et al., 2013). In fact, the number of synthetic vectors used in gene therapy clinical trials has
been steadily increasing over the last 10 years (Gene Therapy Clinical Trials Worldwide, Wiley).
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With neurological diseases specifically affecting different
parts of the brain and even sub-phenotypes of neural cells,
the route of administration is a crucial aspect of nucleic acid
delivery. Intraventricular injection places therapeutics closer to
the subventricular zone, one of the stem cell niches of the brain,
whereas localized intraparenchymal injections may be used to
target a specific part of the brain where neurodegeneration is
occurring or at the location of disease (e.g., brain tumor). In this
focused review, we explore the barriers facing in vivo nucleic
acid delivery and highlight the recent synthetic vehicles and
different strategies that have overcome these challenges to deliver
nucleic acids to the central nervous system (CNS). First, we
briefly discuss nucleic acid protection and targeting the CNS
since these strategies apply to any route of administration. In
later sections, we discuss the common routes of administration
and the specific barriers and vehicular solutions accompanying
each method. While a wide variety of delivery vehicles have been
applied to nucleic acid CNS delivery, we primarily focused on
lipidic and polymeric vehicles with a few selected examples of
inorganic delivery vehicles.
Nucleic Acid Protection
With any route of administration, nucleic acids are susceptible
to chemical degradation and clearance from the body due to
the presence of extracellular nucleases and the immune system
(Abdelhady et al., 2003). While naked nucleic acid delivery
is feasible, carrier-mediated delivery has the potential to be
more efficient by protecting nucleic acids and chaperoning
nucleic acids through the extracellular and cellular barriers to
gene delivery (Figure 1). Thus, this focused review focused
on carrier-mediated delivery of nucleic acids. Typically,
negatively charged nucleic acids are complexed and condensed
with cationic, synthetic materials which allows for nucleic
acids to remain hidden and avoid degradation (Pack et al.,
2005). Common complexation agents used for in vitro gene
transfer include cationic polymers such as polyethylenimine
(PEI), which electrostatically bind to nucleic acids to form
‘‘polyplexes,’’ or polymer-nucleic acid complexes. Similarly,
cationic lipids can also be used to complex nucleic acids to
form ‘‘lipoplexes’’. Another method of enhancing stability
is by modifying the nucleic acid itself so that it avoids
recognition and degradation. For example, altering the ribose
moiety and introducing 2′-fluoro and phosphorothioate
near the terminal region of siRNA duplexes enhanced
stability and prolonged siRNA half-life in vivo (Wang et al.,
2008).
Despite the protection afforded to nucleic acids by
electrostatic complexation, these cationic complexes are
still subject to challenges such as aggregation, toxicity, premature
sequestration by phagocytic cells, and non-specific interaction
with cell membranes and serum proteins (Morille et al.,
2008). When intravenously administered, PEI, one of the
most effective transfection agents in vitro, causes severe
toxic side effects due to polyplex aggregation and strong
electrostatic interactions with cell membranes, proteins and the
extracellular matrix (Al-Dosari and Gao, 2009). To overcome
FIGURE 1 | Stages of nucleic acid delivery into a cell. Nucleic acids are
typically condensed and complexed with a cationic material. This complex
must be recognized by a cell, be internalized and escape the
endosomal-lysosomal degradation pathway. Once in the cell cytoplasm, the
nucleic acid can separate from its vehicle and traffic to its intended target
based on its type.
these challenges, shielding strategies have been developed to
hide nucleic acid delivery vehicle by moieties like poly(ethylene
glycol) (PEG) and albumin (Lu et al., 2006; Laga et al.,
2012).
PEG, a biocompatible, hydrophilic polymer, is commonly
used as a shielding agent for nanoparticles (Immordino
et al., 2006). By creating a barrier around the complex, it
was previously believed that PEG prevents the adsorption
of proteins (Pombo García et al., 2014). However, recent
studies suggest that PEGylation of nanoparticles results in
preferential binding of clusterin, a chaperone protein that
binds to hydrophobic domains of unfolded proteins and
prevents non-specific binding (Schöttler et al., 2016). When
conjugated to delivery vehicles, PEG has been shown to
improve the stability and increase the circulation half-life of
polyplexes, liposomes and other types of vectors. For example,
when conjugated to PEI, PEG prevented the aggregation of
PEI-plasmid DNA complexes in fetal bovine serum-enhanced
media, resulting in complexes that could circulate long enough
for observed localization in the brain (Son et al., 2011). With
encapsulation in PEGylated liposomes, PEI-oligonucleotide
complexes were able to circulate substantially longer and
had plasma concentrations significantly higher than naked
complexes after 60 min (Ko et al., 2009). By any route of
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administration, protecting delivery vehicles with a shielding
agent minimizes aggregation and premature sequestration
and can increase the distribution of the nucleic acids to
desired cells.
Targeting the CNS and Neuronal Cells
Nevertheless, prolonged stability and circulation is not sufficient
for substantial nucleic acid delivery to the brain and spinal
cord because the nervous system is protected by barriers that
grossly prevent the access of therapeutics (Barchet and Amiji,
2009). Cells of the CNS can potentially be accessed through
several contact points including: (1) the blood system; (2) the
cerebral spinal fluid (CSF) in the ventricles or lumbar space;
(3) intraparenchymal fluid in the extracellular space; or (4) nerve
endings that extend outside of the nervous system (Cipolla,
2009). The nervous system is sequestered behind a barrier
system composed of vascular tight junctions and glial elements
that ensheath the blood supply producing a blood-brain and
blood-spinal cord barrier (BBB and BSCB, respectively; Banks,
2016). Each of these compartments represent a potential entry
point as well as unique challenges for neuronal targeting.
Vehicles for systemic delivery must utilize a mechanism that
will facilitate penetration and uptake across the BBB or BSCB
(Spencer and Verma, 2007; Tobinick, 2016). Within the brain,
paracellular flow of neuro-active cytokines is controlled by
pulsation of the blood vessels that mechanically drives a
peristaltic movement of extracellular fluid (Johanson et al., 2011;
Iliff et al., 2013). Meanwhile, gene delivery vehicles directly
administered into the ventricles need to bind to cells of interest
before being washed out of the CNS (Syková and Nicholson,
2008). At the periphery, a vehicle that promotes uptake at
nerve termini and retrograde transport must be able to target a
neuron for transfection and promote travel along the neuronal
cytoskeleleton into the CNS (Hanz and Fainzilber, 2004; von
Bartheld, 2004; Medina-Kauwe, 2007; Tarragó-Trani and Storrie,
2007). Consequently, the advent and development of targeting
ligands has greatly enhanced the capacity of non-viral vectors to
deliver nucleic acids into the CNS.
Drug delivery vehicles have been modified with targeting
agents such as peptides, antibodies, proteins and sugars to
specifically home therapeutics to desired tissues and cell types.
For systemic administration, active targeting is important in
directing the accumulation of vehicles at the brain endothelium.
One commonly used brain-targeting molecule is transferrin,
a glycoprotein that binds to iron. Transferrin receptor is
expressed on the brain endothelium and the binding of
transferrin-decorated nucleic acid delivery vehicles to these
receptors allows for accumulation right outside the brain (Huang
et al., 2007).
Vehicles administered directly into brain by intraventricular
or intraparenchymal methods can also benefit from active
targeting by directing the delivery of nucleic acids to pertinent
cells. For example, to more specifically transfect neural
progenitor cells, Tet 1, a peptide that specifically binds to
neuronal cells, was conjugated to PEI complexes (Kwon et al.,
2010). This Tet1-PEI polymer led to a significantly improved
transfection of neural progenitors by targeted complexes over
untargeted complexes. Thus, targeting moieties can help deliver
nucleic acids to cells and tissues of interest while minimizing
non-specific delivery. In addition, targeting ligands can improve
the intracellular delivery of nucleic acids since many targeting
ligands are endocytosed by cells after binding to its receptor.
Decorated macromolecules such as polyplexes and liposomes
show enhanced uptake in cells compared to their non-targeted
counterparts.
SYSTEMIC DELIVERY
Intravenous administration is one of the most common routes
of administration for macromolecule therapeutics such as
nucleic acids and has the advantage of rapid distribution
and high bioavailability. However, systemic circulation presents
a major challenge for nucleic acid delivery. Naked DNA
has poor stability and is rapidly broken down by nucleases,
sequestered by the liver, and cleared from circulation with a
plasma half-life of mere minutes (Emlen and Mannik, 1984;
Kawabata et al., 1995). To prevent premature degradation
and prolong circulation, nucleic acids have been complexed
with PEGylated cationic materials, such as polymers and
liposomes, which act to shield the polyplex and facilitate
compact packaging and protection. Targeting ligands conjugated
to the synthetic vectors can facilitate recognition of brain
endothelium. However, transport into the brain requires
crossing the BBB, a tight network of endothelial cells that
restricts entry into the brain parenchyma (Gabathuler, 2010).
The brain endothelium has a high expression of efflux
pumps and transporter proteins that exclude nearly 100%
of large-molecule therapeutics and more than 98% of all
small-molecule drugs (Begley, 2003; Pardridge, 2005). Recent
in vivo investigations have focused on transportation across
the BBB and temporarily disrupting the BBB after systemic
administration.
Transport Across the Blood-Brain Barrier
Strategic selection of brain targeting ligands can result in both
recognition of the brain endothelium and facilitated transcytosis
across the BBB. This process, called receptor-mediated
transcytosis, has been demonstrated with cationic proteins
and is believed to be carried out by clathrin-coated pits or
caveolae (Hervé et al., 2008; Table 1). After these materials bind
to the luminal surface of the brain endothelial cells, vesicular
transcytosis is mediated by different proteins and the high
concentration of mitochondria in endothelial cells to cause
exocytosis at the abluminal surface.
The transferrin receptor is frequently targeted for BBB
transcytosis. After binding the transferrin receptor carrier
protein, the transferrin-iron complex is internalized at the apical
side of the brain endothelium and is eventually exocytosed
at the opposite basal surface. Since transferrin receptor is
expressed on the BBB and transcytoses transferrin, it can
be utilized as an uptake pathway into the brain by nucleic
acid vehicles functionalized with transferrin. In one example,
polyamidoamine (PAMAM) dendrimers were decorated with
transferrin by a PEG linker and showed a ∼2-fold higher brain
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TABLE 1 | Properties of effective nucleic acid delivery vehicles.
Property Function Material examples Schematic
Nucleic acid packaging Condense, package, and protect DNA,
RNA, or siRNA
PEI, PLL, PAMAM, liposomes
Stability Prevent premature unpackaging and avoid
sequestration and clearance
PEG, albumin
Targeting CNS localization and cell-specific uptake Peptides, antibodies, proteins
Endosomal escape Facilitate release from the endosome to avoid
lysosomal degradation
Melittin, pH sensitive materials, amines
for proton sponge effect
Cargo release Triggered release or detachment from
nucleic acid
Disulfide linkages
uptake and gene transfer compared to PEGylated dendrimers
alone (Huang et al., 2007). In another example, transferrin
antibodies were used to decorate liposomes that hid plasmid
DNA. This system was able to show a 10-fold greater
β-glucuronidase enzyme activity inmurine brains deficient of the
protein (Zhang et al., 2008).
Another BBB transcytosis moiety is the rabies viral
glycoprotein (RVG) peptide, a 29-amino acid peptide which
binds to nicotinic acetylcholine receptors. Modifying the
peptide sequence to include nine arginines on the C-terminus
allows for complexation with nucleic acids (Kumar et al.,
2007). Upon systemic intravenous administration, these
complexes were able to transvascularly deliver siRNA to the
brain through clathrin- and caveolae-mediated endocytosis by
endothelial cells, which lead to extended lives of encephalitic
mice. The RVG peptide can also modulate the accumulation
of larger vehicles and has delivered macro-structures such as
PAMAM dendrimers (Liu et al., 2009), liposomes (Pulford
et al., 2010), chitosan nanoparticles (Gao et al., 2014),
poly(mannitol-co-PEI) complexes (Park et al., 2015) and
exosomes (Alvarez-Erviti et al., 2011) across the BBB and into
the brain parenchyma. Other targeting agents have included:
angiopep, a peptide that binds to low-density lipoprotein
receptor-related protein-1 (Ke et al., 2009); lactoferrin, an
iron-binding protein of the transferrin family (Huang et al.,
2008, 2010); leptin, a peptide that binds to leptin receptor in
different parts of the brain (Liu et al., 2010); chlorotoxin,
a scorpion-derived venom that is a specific marker for
gliomas (Costa et al., 2013); TGN peptide, a BBB targeting
peptide isolated by phage display (Qian et al., 2013); and
LIMK2 NoLs peptide, a nucleolar translocation signal sequence
derived from the LIM Kinase 2 protein (Yao et al., 2015).
Collectively, these targeting agents have shown to facilitate
the accumulation of PEGylated PAMAM dendrimers, lysine
dendrimers, liposomes, and polymeric polyplexes in the
brain.
Blood-Brain Barrier Disruption
Other methods of systemic nucleic acid delivery focus
on temporarily disrupting the BBB to enhance the
diffusion of vehicles into the brain. These strategies can
be combined with delivery vehicles to further augment
gene transfection. Small molecules, such as mannitol, have
been shown to temporarily open the BBB and allow the
penetration of larger molecules into the brain parenchyma.
Hypertonic solutions of these molecules is believed to
widen tight junctions by shrinking vascular endothelial cells
(Rapoport, 2001). Consequently, the co-administration of
mannitol with RVG-decorated PEI was able to significantly
enhance the distribution of complexes throughout the
brain when compared to carriers alone (Hwang et al.,
2011).
More recently microbubbles, or gas-filled microspheres, have
been coupled with ultrasound as a method to temporarily disrupt
the BBB (Meairs and Alonso, 2007; Panje et al., 2013; Rychak
and Klibanov, 2014; Figure 2). This process, called sonoporation,
creates micropores, permeabilizes cell membranes and breaks
up tight junctions as microbubbles act as local enhancers of
the ultrasound acoustic energy and cavitate causing local shear
flow, microstreams and microjets (Greenleaf et al., 1998; Zhou
et al., 2012; Panje et al., 2013). These BBB openings are large
enough to allow for the permeation of macromolecules into
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FIGURE 2 | Mechanisms of entering the central nervous system (CNS). (A) With receptor-mediated endocytosis, the binding of a ligand to its receptor on the
brain endothelium facilitates cellular endocytosis, vesicular trafficking and eventually exocytosis on the contralateral side into the brain. (B) Microbubble-mediated
disruption of the choroid plexus epithelium breaks tight junctions and creates micropores, allowing for the enhanced penetration of polyplexes into the brain. (C) New
targeting ligands allow for uptake by peripheral neurons and the retrograde transport of cargo along axons to cell bodies in the CNS.
the brain such as immunoglobulin G and 70 kDa dextran
(Sheikov et al., 2004; Choi et al., 2007, 2010, 2011; Xie et al.,
2008). The safety of microbubble-mediated BBB disruption
has been evaluated in rats and macaque monkeys with no
or limited damage to brain tissue and no behavioral or
visual deficits (McDannold et al., 2012; Kobus et al., 2015).
Microbubble-mediated disruption of the BBB has been used
to increase anti-Huntingtin siRNA delivery into the murine
brain to reduce Huntingtin protein levels in animal disease
models (Burgess et al., 2012). In another example, DNA can
be complexed with cationic polymer-decorated microbubbles to
prevent premature degradation. In this manner, microbubble
and DNA complexes were used to markedly enhance the
expression of brain-derived neurotrophic factor and enhanced
green fluorescence protein in murine brains (Huang et al.,
2012a,b). Microbubbles can also be co-administered with
liposomal gene carriers to specifically open a region of the
BBB by focused US, which uses an acoustic lens to center the
US at a specific point (Lin et al., 2015). Co-administration of
microbubbles with dense PEG-coated nanoparticles was able to
open the BBB and transfect a variety of brain cells for at least
28 days with systemic administration (Nance et al., 2014; Mead
et al., 2016).
In some cases, such as brain gliomas and traumatic
brain injury, there is a natural disruption of the BBB.
In small rat brain tumors, there is no BBB permeability;
however, as the tumor grows and neovascularization occurs,
ultrastructural defects in the capillary vessels arise causing a
stark disruption in the tumor (Yamada et al., 1982). This leaky
BBB vasculature can be exploited by gene delivery vehicles as
a facile method of CNS entry and can greatly complement
receptor-mediated transcytosis. PEGylated nanoparticles and
liposomes decorated with receptor-mediated transcytosis ligands
were able to accumulate in gliomas after systemic administration
and delay tumor growth (Lu et al., 2006; Yue et al.,
2014).
CEREBROSPINAL FLUID INJECTION
The CSF is produced by the choroid plexus deep in the
ventricles and drains along paravenous circulation (Cipolla,
2009). The CNS is unique in that it does not have a traditional
lymph system and waste material and metabolites drain from
the extracellular space to the CSF (Iliff et al., 2012). While
non-viral gene delivery into CSF-filled spaces is not as facile
as intravenous administration, it does have the advantages of
avoiding systemic circulation and placing therapeutics in close
proximity to the brain parenchyma (Johanson et al., 2011).
For example, lateral intraventricular injections allow for close
proximity to the subventricular zone, a region of the brain
containing neural progenitor cells, and may be an appropriate
injection site for neurogenesis applications. In addition, there
are excellent access points that are used routinely in the
clinic including a lumbar puncture or intraventricular cannulas
(Belverud et al., 2008; Tobinick, 2016). Substances directly
injected into the CSF circumvent the BBB and distribute in the
brain depending on size and charge. The ependymal barriers
in ventricles are comprised of the choroid plexus cells and in
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the sub-arachnoid space, the arachnoid barrier cells of glia and
pial vessels (Abbott et al., 2006). For intraventricular delivery,
large molecular weight proteins are not free to diffuse into
the brain parenchyma due to the choroid plexus epithelium,
which lines the cavities of the ventricles and the cranial and
spinal sub-arachnoid space and secretes cerebrospinal fluid
(Dohrmann, 1970; Mortazavi et al., 2014). While the ependymal
barrier is not as stringent as the BBB, access and penetration
into the brain parenchyma are still difficult due to the low
diffusion and the constant movement of CSF fluid through the
CNS and back into the bloodstream (Pardridge, 2011). While
ventricular access of therapeutics to the brain is restricted,
delivery to the sub-arachnoid space often results in widespread
brain delivery of small molecular weight proteins (Iliff et al.,
2012).
Designing Vehicles to Overcome Delivery
Barriers
While the choroid plexus ependymal cell layer acts as a barrier,
nucleic acid therapeutics intraventricularly injected are still able
to have some efficacy likely due to the direct sampling of
neural stem cells into the CSF and some penetration into the
parenchyma. Certain formulations of linear PEI were able to
diffuse throughout the ventricular space and transfect neurons
and glia near the edge (Goula et al., 1998). After intraventricular
injection, PEI and DNA complexes have been shown to
transfect neural progenitor cells (Lemkine et al., 2002); while
PEI complexes decorated with Tet1, a peptide that specifically
binds to neuronal cells, bound better to neural progenitor cells
and showed an improved transfection of neural progenitors
over untargeted complexes (Kwon et al., 2010). Other carrier
structures such as liposomes and silica nanoparticles have also
been used as nucleic acid delivery vehicles for intraventricular
administration. Cationic liposomes and organically modified
silica nanoparticles were used to successfully deliver siRNA and
plasmid DNA to neuronal cells in vivo, respectively (Bharali et al.,
2005; Zou et al., 2010). All of these carriers can help protect
nucleic acids as lipoplexes protected mRNA from premature
degradation in CSF for up to 4 h while mRNA alone degraded
within 5 min (Anderson et al., 2004). Peptide-decorated micelles
filled with dexamethasone, a glucocorticoid that facilitates
transport to the nucleus, were able to significantly reduce
infarct size after middle cerebral artery occlusion by gene
delivery.
Recently, multifunctional gene delivery vehicles have been
synthesized with the aim of overcoming many of the barriers
to gene delivery such as premature unpackaging, endosomal
escape, and DNA release (Table 1). A statistical copolymer of
N-(2-hydroxypropyl)methacrylate (HPMA), oligo-L-lysine, and
melittin was developed for gene delivery after intraventricular
injection (Schellinger et al., 2013). The HPMA monomers
were for stability, the lysines were developed for DNA
condensation and packaging, and the melittin, a membrane-lytic
peptide developed from honey bee venom, was included
to enhance endosomal escape after vesicular uptake. This
polymer efficiently condensed DNA into stable particles
to form polyplexes and increased brain transfection about
35-fold compared to melittin-free analogs. Another polymer
designed for in vivo gene delivery utilized a double-headed
reversible addition-fragmentation chain transfer agent and a
ring-opening polymerization initiator to create two different
polymer segments that contribute to different aspects of
gene delivery (Wei et al., 2013). This copolymer, PCL-SS-
p[(GMA-TEPA)-s-OEGMA], consisted of a block of poly(ε-
caprolactone) (PCL) connected by a reducible disulfide to
a statistical copolymer of tetraethylenepentamine (TEPA)-
decorated poly(glycidyl methacrylate) (GMA) and oligo(ethylene
glycol) monomethyl ether methacrylate (OEGMA). The TEPA
amine groups bind to and condense nucleic acids to form
polyplexes while the hydrophobic PCL and hydrophilic OEGMA
provide extracellular stability. After polyplex internalization,
the amine groups contribute to endosomal escape by pH
buffering and the internal disulfide bond can be reduced by
cytosolic glutathione facilitating polyplex destabilization and
nucleic acid release. These polyplexes were shown to have
diameters less than 200 nm, transfected HeLa cells more
efficiently than PEI in vitro, and delivered luciferase genes to
the brain more efficiently than its individual components. To
improve transfection further, the amines of this polymer were
guanidinylated and investigated in vivo. The delocalized charge
of guanidinium groups is attributed to stronger interaction
with DNA than amines and greater cell internalization by
interacting with cell surface phosphates and sulfates (Wehling
et al., 1975; Cheng et al., 2013). While guanidinium groups
show improved transfection in vitro, they did not translate
to augmented transfection in vivo likely due to premature
unpackaging as guanidinium groups have a predilection for
sulfates of heparan sulfate proteoglycans over nucleic acid
phosphate groups (Choi et al., 2015). Recently, we developed
a new endosomal-escaping, polymeric vehicle that has a
triggered exposure of a membrane lytic peptide when in the
acidic pH of endosomes (Cheng et al., 2016). This polymer,
called Virus-Inspired Polymer for Endosomal Release (VIPER),
is composed of a cationic block, poly(OEGMA)-co-poly(2-
(dimethylamino)ethyl methacrylate) (p(OEGMA-DMAEMA)),
for nucleic acid condensation and a pH-sensitive block, poly(2-
diisopropylaminoethyl methacrylate)-co-poly(pyridyl disulfide
ethyl methacrylate) (p(DIPAMA-PDSEMA)), for triggered
display of a membrane lytic peptide, melittin, in acidic
conditions. VIPER polyplexes, or polymer-DNA complexes,
showed membrane-lytic activity only in the acidic conditions
of the cell endosome and efficient gene transfer to a variety
of cell types and therefore may be useful for CNS gene
transfer.
Cerebrospinal fluid injections into other areas of the CNS
have also been employed for the administration of nucleic
acid carriers. After injection into the cisterna magma of rats,
liposomes delivered luciferase plasmid throughout the brain
that was still detectable 7–10 days later (Hauck et al., 2008).
Interestingly, when the same system was directly injected into
the parenchyma, luciferase expression was not as distributed. A
micelle system of PEG-aspartic acid polymer was able to provide
sustained protein expression with minimal immunogenicity
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(Uchida et al., 2013). Nucleic acid administration into the lumbar
subarachnoid space has also been accomplished with a variety
of delivery vehicles. Poly(lactic-co-glycolic acid) microparticles
containing plasmid DNA that encodes IL-10 were able to relieve
neuropathic pain in rats for greater than 74 days (Soderquist
et al., 2010). PEI complexes decorated with a peptide from nerve
growth factor were able to more specifically transfect dorsal
root ganglia (Zeng et al., 2007). By creating Tat decorated-PEI
complexes with magnetic iron beads, researchers were able to
use magnetic fields to direct the movement of DNA complexes
into remote areas away from the injection site in rat spinal
cords (Song et al., 2010). While sufficient levels of gene
transfection are achieved after CSF injection, the choroid plexus
epithelium still prevents most of the vehicles from entering the
parenchyma which results in a significant loss of transfection
potential.
Choroid Plexus Epithelium Disruption
In a similar fashion to BBB disruption, the choroid plexus
epithelium may be transiently disrupted by microbubbles
and ultrasound to allow for the enhanced penetration
of materials into the brain parenchyma from the CSF
fluid. Custom microbubbles were prepared and did
not aggregate with aforementioned PCL-SS-p[(GMA-
TEPA)-s-OEGMA] polyplexes (Tan et al., 2016). In
in vitro transwell assays, these microbubbles were able
to sonoporate immortalized choroid plexus monolayers
to allow for the enhanced flow through of 5 kDa PEG
and 70 kDa dextran. Upon in vivo administration into
murine ventricles, the microbubbles and ultrasound
were able to significantly increase polyplex transfection
of cells with luciferase compared to polyplexes alone or
polyplexes and microbubbles without ultrasound. Temporary
microbubble-mediated disruption of the choroid plexus
epithelium seems like a viable strategy to enhance the
penetration of polyplexes and may garner more research in
the future.
INTRAPARENCHYMAL INJECTION
Intraparenchymal injection is the most direct access to discrete
anatomy and cells of the brain and spinal cord. However, there
are several critical challenges notwithstanding the inherent risk
of an invasive CNS injection. Injection or probe placement alone
can create a reactive gliosis that may limit the transport of a
therapeutic or exacerbate the disease (Polikov et al., 2005; Potts
et al., 2013). Methods for convection enhanced delivery and the
use of small caliber pipettes can mitigate some of these concerns
and allow targeted delivery of relatively large volumes without
harm (Mano et al., 2016). Once in the parenchyma, therapeutics
have variable degrees of diffusion and entrapment that can be
modeled based on protein or drug size and composition (Patlak
et al., 1983; Ghersi-Egea et al., 2002; Hrabe et al., 2004; Nicholson
et al., 2011). After parenchymal diffusion, clearance is regulated
by the lymphatic system which is comprised of the glia cells
that ensheath the venous system of the brain which is localized
primarily near the dural surfaces (Iliff et al., 2012; Louveau
et al., 2015). In general, small molecular weight substances
are able to diffuse readily and are cleared in minutes. Larger
molecular weight substances may either lack significant diffusion
or be cleared over a course of hours (Syková and Nicholson,
2008).
Bolus Injection
While the location of intraparenchymal injections into the brain
can vary, the same type of nucleic acid delivery vehicles is
still utilized. PEI decorated with 2 kDa PEG chains resulted
in improved gene delivery after intrathecal administration into
the lumber spinal cord subarachnoid space compared to PEI
(Tang et al., 2003). Reducible arginine-PAMAM dendrimers
were able to knockdown genes after injection into the cortex
(Kim et al., 2010). Biodegradable poly(β-amino esters) that were
lyophilized and stored for over 2 years effectively transfected
brain glioblastomas, demonstrating long-term storage and
efficacy for clinical translation (Guerrero-Cázares et al., 2014).
Reversibly conjugated siRNA to liposomes was able to efficiently
silence genes in oligodendrocytes after administration into the
corpus callosum (Chen et al., 2010). Liposomes encapsulating
siRNA have also shown effective gene knockdown of the
GluN1 subunit of NMDA receptors in neurons (Rungta et al.,
2013). Targeting agents have also been used to enhance the
nucleic acid delivery vehicles. PEGylated PEI was targeted with
folate, which binds to folate receptor often overexpressed on
cancer cells, and liposomes were targeted with transferrin to
improve the delivery of plasmids and siRNA after injection
into the right striatum (Cardoso et al., 2008; Liang et al.,
2009).
Sustained Delivery
The compact and tortuous morphology of the brain parenchyma
severely limits the diffusion of nucleic acid delivery vehicles
away from the administration site. To overcome this, sustained
delivery is utilized to constantly introduce more vehicles and
increase the diffusion throughout the brain. In one example, an
osmotic pumpwas able to continually inject siRNA and liposome
complexes into the frontal lobe to knockdown the resistance of
gliomas to therapy (Kato et al., 2010). This treatment significantly
sensitized tumors to the chemotherapeutic agents and extended
the survival of mice. In other cases, a cannula is implanted in
the brain for acute direct injections or chronic administration.
Repeated dosing of siRNA against toxic Huntingtin protein
in β-cyclodextin carriers was able to alleviate motor deficits
in a Huntington’s disease mouse model (Godinho et al.,
2013).
Like the osmotic pump, convection-enhanced delivery
is administered intraparenchymally and used to continually
introduce therapeutics. A cannula is typically inserted
stereotaxically into a designated spot in the brain and a
therapeutic fluid is continuously injected under positive
pressure (Allard et al., 2009). The administration of siRNA
by convection-enhanced delivery was able to silence genes in
oligodendrocytes (Querbes et al., 2009) and silence Huntingtin
gene in a widespread manner across the brain (Stiles et al.,
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2012). When a cell-penetrating peptide, TAT, was attached
to liposomes, gene transfection increased in vivo; however,
expression was restricted to the vicinity of the infusion catheter
(MacKay et al., 2008). When comparing positively and negatively
charged liposomes, anionic liposomes were better able to spread
throughout the brain parenchyma with similar transfection
levels (Kenny et al., 2013).
RETROGRADE TRANSPORT
While there have been substantial advances in brain-targeted
delivery to treat diseases that affect specific parts of the brain
like Alzheimer’s Disease (Kumar et al., 2007; Spencer and
Verma, 2007; Yu et al., 2011), few therapeutic options are
available for degenerative diseases that affect motor neurons
because many of the potential genes and siRNA drugs show
limited diffusion and penetration to motor neurons deep in
the CNS parenchyma (Monani, 2005; Mitchell and Borasio,
2007). For decades, classes of viruses have been known to
infect neuronal projections in the periphery and undergo
retrograde axonal transport into the brain and spinal cord
(LaVail and LaVail, 1972; Salinas et al., 2010). Thus, several lab
have begun to systematically mutate adeno-associated vectors
in order to expand their clinical application and increase
delivery into the CNS (Maheshri et al., 2006; Kotterman and
Schaffer, 2014), innovative strategies have been adopted to
utilize retrograde axonal transport to deliver biologics into
the spinal cord (Xu et al., 2005; Hollis et al., 2008; Snyder
et al., 2011). As a result, these viruses have been engineered
and shown to be effective for remote gene transfer into
the CNS after intramuscular injection to induce neurotrophic
factor expression in animal models of neurodegenerative
disease (Kaspar et al., 2003; Azzouz et al., 2004; Petruska
et al., 2010; Benkhelifa-Ziyyat et al., 2013; Hirano et al.,
2013).
Recently, small targeting agents have been used to direct the
trafficking of cargo into the CNS after peripheral administration
(Figure 2). Tetanus toxin subunit-C (TTC), an atoxic fragment
of tetanus toxin that contains the ganglioside-binding site, is
able to mediate uptake at both pre- and post-synaptic at nerve
termini to allow retrograde transport passage of TTC within
neurons (Price et al., 1975; Schwab et al., 1979). Consequently,
these trans-synaptic properties of TTC have been exploited as a
fusion protein to enable delivery into the spinal cord after TTC
uptake at peripheral nerve termini (Francis et al., 2004; Chian
et al., 2009; Li et al., 2009). While the TTC fusion-proteins were
shown to increase delivery into the spinal cord, these studies
were not able to discern a therapeutic benefit, which may suggest
that that TTC-fusions do not escape the endosome after uptake
and remain sequestered in the vescicle that mediated uptake.
More recently, a targeted axonal import peptide (TAxI) was
identified by in vivo phage display. The TAxI peptide was able
to mediate uptake and delivery of an active Cre recombinase
into the nucleus of spinal cord motor neurons after hind limb
intramuscular injection (Sellers et al., 2016). These data suggest
that small peptides are not only able tomediate synaptic uptake at
nerve termini and retrograde transport within neurons, but they
allow for functional protein cargo delivery via the neuron. While
there have yet to be any reports of synthetic, retrograde nucleic
acid delivery into the CNS, the discovery of targeting ligands
that mediate uptake by neurons in the periphery, transport
within neurons to the CNS, and release of active cargo into the
cytoplasm has the potential of opening a whole new delivery
route for non-viral technologies to target motor neurons for gene
delivery.
Another route of administration that takes advantage
of retrograde transport through neurons is intranasal
administration. After introduction into the nasal cavity,
molecules are believed to travel along olfactory nerve pathways
and end up in the brain parenchyma and CSF by bypassing the
BBB (Patel et al., 2009). Peptides, proteins, and small molecules
have shown to be able to be delivered into the CNS after
intranasal administration. While this route is non-invasive, the
nasal cavity has many barriers including enzymes and mucous;
furthermore, compounds similar to those that have shown CNS
delivery have reportedly not entered the CNS after intranasal
administration (Dhuria et al., 2010). The formulation and
method of delivery may affect retrograde transport as well as
other experimental factors such as head position, volume, pH
and osmolarity (Dhuria et al., 2010). Plasmid DNA ranging
from 3.5 kb to 14.2 kb were able to show absorption and brain
distribution after intranasal administration (Han et al., 2007).
Intranasal delivery of an telomerase-inhibiting oligonucleotide
was able to prolong the survival of human tumor-bearing rats
by over 30 days (Hashizume et al., 2008). Carriers for intranasal
gene delivery follow the same principles as other vehicles
administered by other routes. Polymeric vehicles comprised
of methoxy PEG, poly(ε-caprolactone) and TAT peptide
demonstrated better delivery of siRNA to the brain than naked
siRNA or carrier-mediated intravenous delivery (Kanazawa
et al., 2013).
CONCLUSION
While viral vectors are still the main type of vehicles used
in clinical trials, non-viral vectors are gaining traction due
to their potential safety advantages, greater customization,
ease of manufacturing and ability to deliver all nucleic
acid varieties (Niidome and Huang, 2002; Thomas et al.,
2003). The ability of viral vectors to permanently alter the
genome and activate the immune system make non-viral
vectors more compelling for clinical trials. However, the lower
efficacy and transfection levels by synthetic vectors hinder
their wide clinical use. For any application, nucleic acid
delivery vehicles face cellular obstacles such as recognition by
pertinent cells, internalization into cells, escaping the lysosomal
degradation pathway and unpackaging the nucleic acids in
the cell cytosol. Delivery into the CNS presents an even
greater challenge due to the supracellular BBB and BSCB. An
apropos administration route must be chosen to maximize
therapeutics at the treatment site (i.e., direct injections);
however, caution must be heeded in avoiding unnecessary
damage to healthy tissues by direct administration into the
CNS (i.e., intravenous and peripheral administration). Each
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route of administration has its advantages and disadvantages,
as well as local barriers, as previously discussed. Fortunately,
the advances in vehicular design, materials and synthesis
described above have allowed for specific engineering of
gene delivery vehicles to overcome these challenges and step
closer to the transfection efficiency of viruses. Improvements
such as nucleic acid shielding and targeting have lessened
premature degradation and increased the localization of cargo
in the CNS. Advances in crossing the BBB and sustained
delivery directly into the brain allow for improved gene
transfection and a step closer to clinical application. Meanwhile,
new techniques such as microbubble-mediated sonoporation
and small molecule-mediated retrograde transport allow the
permeation of otherwise excluded vehicles into the brain and
spinal cord. All of these examples can serve as guidelines and
inspiration for the next generation of synthetic gene delivery
vectors. With these improvements, we anticipate that synthetic
delivery systems will be applied more successfully for nucleic
acid therapies in animal models of CNS disease and will make
significant progress toward clinical evaluation in the upcoming
years.
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